Recombinant Zoster vaccine (Maxhealth)

Main purpose: To evaluate the protective efficacy of recombinant herpes zoster vaccine (CHO cells) (hereinafter referred to as "experimental vaccine") in preventing herpes zoster in people aged 40 years and above after 30 days of full immunization with a 0-2 month immunization schedule. Secondary objectives: 1) To evaluate the protective efficacy of the trial vaccine in preventing herpes zoster 30 days after full immunization in people aged 40-49 years, 50-59 years, 60-69 years, and ≥70 years with a 0-2 month immunization schedule; 2) To evaluate the protective efficacy of the trial vaccine in preventing any degree [Zoster Brief Pain Inventory (ZBPI) score > 0] and preventing severe (ZBPI score ≥ 3) postherpetic neuralgia (PHN) in effective endpoint cases in people aged 40 years and above, 40-49 years, 50-59 years, 60-69 years, and ≥70 years with a 0-2 month immunization schedule; 3) To evaluate the safety of the trial vaccine; 4) To evaluate the immunogenicity and immune persistence of the trial vaccine.